ACT Brief: AI in Invoice Processing, Botanical Medicines and FDA Pathways, and Connected Trial Finance Systems

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In part three of his interview, Patrick Mizer, chief technology officer at Ledger Run, describes how agentic AI is being applied to invoice processing, one of the most labor-intensive bottlenecks in site payments. His company built an agentic AI flow that ingests emailed invoices, screens for protected health information, decomposes components, and validates them against systems with accuracy high enough that QC experts cannot distinguish AI outputs from human work in blind testing.
• In the latest Beyond Compliance episode, Joel Stanley, CEO of AJNA BioSciences, discussed why botanical therapies need pharmaceutical-grade standardization and clinical evidence to earn physician trust and insurance coverage. Variability in plant genetics, growing region, and cultivation practices can meaningfully change chemical makeup even when the label stays the same, making consistency the central challenge for botanical medicine development.
• In a new contributed article from IQVIA, authors examined how fragmented financial systems have become constraints limiting visibility, slowing execution, and increasing risk across the trial lifecycle. A connected ecosystem with AI integration shifts clinical trial finance from manual coordination toward automated visibility and real-time decision support, reducing the manual effort that Frost and Sullivan's survey of 300 clinical ops executives identified as the top challenge.

That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.